Article Text

Download PDFPDF

39 Drug coated balloon only angioplasty for stable angina in routine clinical practice
Free
  1. Ioannis Merinopoulos1,
  2. Tharusha Gunawardena2,
  3. Natasha Corballis2,
  4. Tim Gilbert2,
  5. Clint Maart2,
  6. Johannes Reinhold2,
  7. Alisdair Ryding2,
  8. Toomas Sarev2,
  9. Chris Sawh2,
  10. Sreekumar Sulfi2,
  11. Upul Wickramarachchi2,
  12. Trevor Wistow2,
  13. Vassilios Vassiliou3,
  14. Simon Eccleshall2
  1. 1University of East Anglia, Norfolk & Norwich University Hospital, Colney Lane, Norwich, NFK NR4 7UY, United Kingdom
  2. 2NNUH
  3. 3UEA

Abstract

Introduction The recent BASKETSMALL2 trial demonstrated safety and efficacy of drug coated balloon (DCB) angioplasty for de novo small vessel disease. Registry data have demonstrated that DCB angioplasty is safe; however, the majority of these studies are limited due to long recruitment time and small number of patients with DCB compared to drug eluting stents (DES). Our aim was to investigate if DCB-only strategy is safe to incorporate in routine clinical practice.

Methods We identified all patients treated for stable angina and de novo disease in our institution from January 2015 till November 2019. During that period an equivalent number of patients were treated with DCB-only or DES-only strategy on a yearly basis.The primary endpoint was all cause mortality. The secondary endpoints were cardiovascular mortality, acute coronary syndrome (ACS), ischaemic stroke, major bleeding and target lesion revascularisation (TLR). Data were obtained from the hospital episodes statistics from NHS digital. Clinical and angiographic data were collected from our prospectively collated database and supplemented from electronic records as required. All angiograms were reviewed to confirm accuracy of angiographic data and determine TLR.

Results A total of 1302 patients were identified. HES data were not obtained for 65 patients who had opted-out, therefore 1237 were included in the analysis; 544 were treated with DCB and 693 with DES. The average age for the DCB-group was 67.9±10.2 years old (79% male); while for the DES group it was 67.9±9.7 years old (78.1% male). The average follow up was 1339±514 days and 1354±527 days for the DCB and DES group respectively. Table 1 shows the differences between the groups in terms of clinical and angiographic characteristics.The all cause mortality was 35 (6.4%) and 59 (8.5%) for the DCB and DES group respectively. Kaplan Meier estimator plot did not show a significant difference between the groups. There was no difference between the groups in any of the secondary endpoints (cardiovascular mortality, ACS, stroke, major bleeding and TLR). On multivariable COX regression analysis (Table 2) age, frailty and hypercholesterolaemia were the only independent predictors of mortality.

Abstract 39 Table 1

Clinical and angiographic differences between the groups

Abstract 39 Table 2

Multivariable cox regression analysis for all-cause mortality

Conclusion Our real world data from a large, contemporary cohort of stable angina patients, including predominantly large vessels, demonstrate that DCB only angioplasty is safe compared to DES in terms of all major cardiovascular endpoints including TLR.

Conflict of Interest N/A

  • stable angina
  • drug coated balloon
  • angioplasty

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.